SILVER SPRING, MD — The US Food and Drug Administration has scheduled a public hearing to address issues surrounding the “safety, manufacturing, product quality, marketing, labeling, and sale” of products containing hemp-derived cannabinoids such as CBD.
Tags: cannabidiol (CBD), cannabiniol, CBD, Food and Drug Administration, Scott Gottlieb
